Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Raidium

Explore full profile

Raidium foundation model: Radiology augmented GPT to tackle the complexity of precision medicine

Roubaix, FranceFounded 2022Biotech & Life Sciences
Valuation $50–100M Last recorded · 2024
Revenue <$1M Latest reported FY
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Raidium and the history behind them.

About Raidium

Raidium is a cutting-edge startup operating in the healthcare technology sector, specifically focusing on radiology. The company leverages advanced Artificial Intelligence (AI) to enhance precision medicine by improving the characterization of imaging biomarkers. Imaging biomarkers are measurable indicators found in medical images that can help diagnose and monitor diseases. Raidium's AI platform is designed to assist radiologists, who often face the challenge of analyzing vast quantities of medical images.

Read full description

Raidium employs a sophisticated AI technique known as Self-Supervised Learning (SSL). Unlike traditional supervised learning, which requires labeled data for training, SSL allows the AI to learn from large, unlabeled datasets. This makes the AI more versatile and capable of performing multiple tasks, such as analyzing different types of medical images. Additionally, Raidium's AI is multimodal, meaning it can process various types of inputs, including text, images, and sound. This capability enhances its utility in diverse medical scenarios.

The primary clients of Raidium are healthcare providers, including hospitals and diagnostic centers, that seek to improve the accuracy and efficiency of their radiology departments. By integrating Raidium's AI platform, these institutions can better manage the overwhelming volume of medical images, leading to faster and more accurate diagnoses.

Raidium operates in the global healthcare market, with a particular focus on regions that are rapidly adopting AI technologies in medical practices. The company's business model revolves around offering its AI platform as a subscription-based service. Healthcare providers pay a recurring fee to access the platform, which includes regular updates and support. This model ensures a steady revenue stream for Raidium while providing continuous value to its clients.

Revenue is generated through subscription fees, and potentially through partnerships with medical institutions and research organizations. The company also ensures compliance with data protection regulations, such as the General Data Protection Regulation (GDPR), by pseudonymizing personal medical data to protect patient privacy.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2022
Headquarters
Roubaix, France
Employees
52
Open positions
2
Dealroom signal
91.2/100
Industry
Health
Sub-industry
BioTechnology, Health Platform
Sector
Biotech & Life Sciences, Biotechnology, Biomarkers, Medical Imaging, Core AI, Precision Medicine
Technology
Artificial Intelligence, Deep Tech, Machine Learning, Deep Learning
Business model
SaaS
Client focus
b2b

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC May 2025 $0 — Debiopharm Group ↗
SEED✓Equity / VC Nov 2024 $18M $70M Founders Future · Techmind VC · Newfund · Debiopharm Group ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026
2025
2024
2023 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Raidium website traffic

Latest recorded traffic for Raidium is 5.2K monthly website visits, up 333.3% over the last three months. Raidium's team grew 30% over the past year.

Latest monthly visits5.2K 3-month web change+333.3% 1-year team growth+30%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed7 investors entered at this stage

  • European Innovation Council
  • Newfund
  • Kurma Partners
  • Founders Future
  • Techmind VC
  • Debiopharm Group
  • Galion.exe

Series A1 investor entered at this stage

  • EIC Fund

Other known investors3 additional known investors

  • 21st by CentraleSupélec
  • Paris Biotech Santé
  • Sharpstone Capital
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇫🇷 France95.7%
🇱🇺 Luxembourg2.1%
🇺🇸 United States2.1%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Raidium on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Raidium’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.